Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

People with epilepsy have a high risk of developing depressive disorders, and people with primary depressive disorders have a high risk of developing epilepsy. Furthermore, a lifetime history of depressive disorders has been associated with a poor response of the seizure disorder to pharmacotherapy and epilepsy surgery. The aim of this Review is to identify the principal neurobiological pathogenic mechanisms of depressive disorders with the potential to facilitate the epileptogenic process or cortical hyperexcitability in experimental animal studies or those that can aggravate known pathogenic mechanisms of epilepsy in human beings. These mechanisms include (1) a hyperactive hypothalamic-pituitary-adrenal axis; (2) structural and functional abnormalities of cortical structures; (3) increased glutamatergic and decreased GABAergic and serotonergic activity; and (4) immunological abnormalities. The data presented in this Review provide experimental evidence that might begin to explain the bidirectional relation between depressive disorders and epilepsy and that can be regarded as a source for future research.

Original languageEnglish (US)
Pages (from-to)1093-1102
Number of pages10
JournalThe Lancet Neurology
Volume11
Issue number12
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Depressive Disorder
Epilepsy
Depression
Drug Therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? / Kanner, Andres M.

In: The Lancet Neurology, Vol. 11, No. 12, 12.2012, p. 1093-1102.

Research output: Contribution to journalArticle

@article{2911caa0851544e69e21ab1a348dceb2,
title = "Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?",
abstract = "People with epilepsy have a high risk of developing depressive disorders, and people with primary depressive disorders have a high risk of developing epilepsy. Furthermore, a lifetime history of depressive disorders has been associated with a poor response of the seizure disorder to pharmacotherapy and epilepsy surgery. The aim of this Review is to identify the principal neurobiological pathogenic mechanisms of depressive disorders with the potential to facilitate the epileptogenic process or cortical hyperexcitability in experimental animal studies or those that can aggravate known pathogenic mechanisms of epilepsy in human beings. These mechanisms include (1) a hyperactive hypothalamic-pituitary-adrenal axis; (2) structural and functional abnormalities of cortical structures; (3) increased glutamatergic and decreased GABAergic and serotonergic activity; and (4) immunological abnormalities. The data presented in this Review provide experimental evidence that might begin to explain the bidirectional relation between depressive disorders and epilepsy and that can be regarded as a source for future research.",
author = "Kanner, {Andres M}",
year = "2012",
month = "12",
doi = "10.1016/S1474-4422(12)70201-6",
language = "English (US)",
volume = "11",
pages = "1093--1102",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "12",

}

TY - JOUR

T1 - Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?

AU - Kanner, Andres M

PY - 2012/12

Y1 - 2012/12

N2 - People with epilepsy have a high risk of developing depressive disorders, and people with primary depressive disorders have a high risk of developing epilepsy. Furthermore, a lifetime history of depressive disorders has been associated with a poor response of the seizure disorder to pharmacotherapy and epilepsy surgery. The aim of this Review is to identify the principal neurobiological pathogenic mechanisms of depressive disorders with the potential to facilitate the epileptogenic process or cortical hyperexcitability in experimental animal studies or those that can aggravate known pathogenic mechanisms of epilepsy in human beings. These mechanisms include (1) a hyperactive hypothalamic-pituitary-adrenal axis; (2) structural and functional abnormalities of cortical structures; (3) increased glutamatergic and decreased GABAergic and serotonergic activity; and (4) immunological abnormalities. The data presented in this Review provide experimental evidence that might begin to explain the bidirectional relation between depressive disorders and epilepsy and that can be regarded as a source for future research.

AB - People with epilepsy have a high risk of developing depressive disorders, and people with primary depressive disorders have a high risk of developing epilepsy. Furthermore, a lifetime history of depressive disorders has been associated with a poor response of the seizure disorder to pharmacotherapy and epilepsy surgery. The aim of this Review is to identify the principal neurobiological pathogenic mechanisms of depressive disorders with the potential to facilitate the epileptogenic process or cortical hyperexcitability in experimental animal studies or those that can aggravate known pathogenic mechanisms of epilepsy in human beings. These mechanisms include (1) a hyperactive hypothalamic-pituitary-adrenal axis; (2) structural and functional abnormalities of cortical structures; (3) increased glutamatergic and decreased GABAergic and serotonergic activity; and (4) immunological abnormalities. The data presented in this Review provide experimental evidence that might begin to explain the bidirectional relation between depressive disorders and epilepsy and that can be regarded as a source for future research.

UR - http://www.scopus.com/inward/record.url?scp=84869121865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869121865&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(12)70201-6

DO - 10.1016/S1474-4422(12)70201-6

M3 - Article

C2 - 23021976

AN - SCOPUS:84869121865

VL - 11

SP - 1093

EP - 1102

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 12

ER -